Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus
Pfizer shares rose 2.7% to $27.22 Friday after the FDA granted Priority Review to its hemophilia drug HYMPAVZI, with a decision expected by mid-2026. Trading volume reached 30 million shares. The company also launched the TrumpRx discount program, offering cash discounts on over 30 drugs. The White House said TrumpRx.gov debuted Thursday with “most-favored nation” pricing on 40 branded drugs.